Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

71

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world’s largest market for drugs.

http://feeds.reuters.com/~r/reuters/healthNews/~3/nA3PgKI2ycE/regeneron-sanofi-wins-u-s-approval-for-expanded-use-of-skin-drug-idUSKBN1QS2GS